Clinical trial
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
NCT05947448 is registered in ClinicalTrials.gov with Hasten Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
- Lead sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 22, 2024
- Completion date
- December 31, 2025
- Enrollment
- 1,215 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.